Background Various observations have suggested that the course of COVID-19 might be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab compared with those not receiving rituximab. We aimed to investigate whether treatment with rituximab is associated with severe COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases.Methods In this cohort study, we analysed data from the French RMD COVID-19 cohort, which included patients aged 18 years or older with inflammatory rheumatic and musculoskeletal diseases and highly suspected or confirmed COVID-19. The primary endpoint was the severity of COVID-19 in patients treated with rituximab (rituximab group) compared with patients who did not receive rituximab (no rituximab group). Severe disease was defined as that requiring admission to an intensive care unit or leading to death. Secondary objectives were to analyse deaths and duration of hospital stay. The inverse probability of treatment weighting propensity score method was used to adjust for potential confounding factors (age, sex, arterial hypertension, diabetes, smoking status, body-mass index, interstitial lung disease, cardiovascular diseases, cancer, corticosteroid use, chronic renal failure, and the underlying disease [rheumatoid arthritis vs others]). Odds ratios and hazard ratios and their 95% CIs were calculated as effect size, by dividing the two population mean differences by their SD. This study is registered with ClinicalTrials.gov, NCT04353609.

No abstract

No abstract

No abstract

Prostate cancer (Pca) is the most commonly diagnosed cancer affecting men in France. Before the age of 75 years old, 1 in 8 French men will have Pca. Androgen deprivation therapies (ADT) remain the standard of care. Such therapies induces significant bone loss. Bone-remodelling cycle depends on the androgen synthesis signalling pathways. Furthermore, age-specific hormonal decline plays a key role in the decrease in bone mass. As a result, the older the patients, the more likely they are to have osteoporosis if they are treated with hormone therapy. Their risk of osteoporotic fracture has an impact on their quality of live and their capacity of independent living. In recent years, newer hormone therapies (acetate abiraterone, enzalutamide, apalutamide and darolutamide) have proved efficient in metastatic castration-resistant Pca (mCRPC) patients as well as in hormone naïve patients, and actually in non-metastatic diagnosis. The combination of these treatments with ADT highly inhibit androgen production pathways. They are prescribed to aged patients undergoing bone density loss after first generation anti-androgen treatment. Specific recommendations for bone health management in Pca patients are currently lacking. To date, bone mineral density in patients treated with second-generation hormone therapy has never been assessed in a prospective study. This review aims at reviewing what is known about the impact of second-generation hormonotherapy on bone microenvironment.

No abstract

No abstract

Background: Cancer nurses have an important role in advocating both for nurses and for patients. They are of great importance in advocating for patients, being their voice and educating them. However, nurses also have a significant role in advocating for nurses on the level of education and policymaking. Cancer nurses can be leaders in different facets within their profession. In caring for patients, they have a vital role in prevention, education, raising awareness and caring for patients and their significant others. Furthermore, cancer nurses show an increasing need to have a role in influencing policy, legislation and in lobbying. One of the aims of the European Oncology Nursing Society's (EONS) advocacy working group is to create a toolkit for nurses to use in their advocacy activities.Methods: A semi structured literary review was conducted. Also, other toolkits were assessed and other models of advocacy were identified.Results: So far have shown different definitions for nursing advocacy. Research has shown that it is mostly clear what is meant with advocating for patients. However nurses have different definitions for advocating as a whole. A guide will be developed that improves cancer nursing status and recognition in Europe containing 2 parts. 1) Introduction to Advocacy/ understanding and 2) advocacy tools. Part 1 will contain a definition, models of advocacy suited for cancer nurses, barriers, the why and when to advocate and targets for advocating. Part 2 of the toolkit will go into tools on how to influence policy, providing of information and training, good practices, public education and involvement and development of an advocacy strategy.Conclusions: At EONS14, further results will be presented on development of this advocacy toolkit for cancer nurses.Legal entity responsible for the study: EONS.